Use of Diuretics in the Treatment of Heart Failure in the Elderly

Clinics in Geriatric Medicine

Volumn 23, Issue 1, 2007, Pages 107-121

  Sica, Domenic A ^a   Gehr, Todd W B ^a   Frishman, William H ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ALDOSTERONE ANTAGONIST; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CANRENONE; CARBONATE DEHYDRATASE INHIBITOR; CHLORINE; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; ETACRYNIC ACID; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; MAGNESIUM; METOLAZONE; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM SPARING DIURETIC AGENT; SODIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; TRIAMTERENE;

BED REST; BLOOD PRESSURE REGULATION; DISEASE EXACERBATION; DISEASE SEVERITY; DISORDERS OF ACID BASE BALANCE; DIURESIS; DIURETIC THERAPY; DRUG ABSORPTION; DRUG HALF LIFE; DRUG POTENCY; ELDERLY CARE; ENDOCRINE DISEASE; FLUID INTAKE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; KIDNEY FUNCTION; METABOLIC ALKALOSIS; PRESCRIPTION; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SODIUM ABSORPTION; SODIUM INTAKE; SODIUM RESTRICTION; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES; URIC ACID URINE LEVEL;

AGED; CARDIOVASCULAR AGENTS; CLINICAL TRIALS; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33751181459     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2006.08.006     Document Type: Review

References (63)

1. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
2. HFSA 2006 comprehensive heart failure practice guidelines. Executive summary. J Card Fail 12 (2006) 10-38
3. Arnold J.M., Liu P., Demers C., et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 22 (2006) 23-45
4. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure (update 2005). Eur Heart J 26 (2005) 1115-1141
5. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 6 (2005) 1116-1143
6. Faris R., Flather M.D., Purcell H., et al. Diuretics for heart failure. Cochrane Database Syst Rev 1 (2006) CD003838
7. Aurigemma G.P., Gottdiener J.S., Shemanski L., et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 37 (2001) 1042-1048
8. de Giuli F., Khaw K.T., Cowie M.R., et al. Incidence and outcome of persons with a clinical diagnosis of heart failure in a general practice population of 696,884 in the United Kingdom. Eur J Heart Fail 7 (2005) 295-302
9. Kitzman D.W. Diastolic heart failure in the elderly. Heart Fail Rev 7 (2002) 17-27
10. Sun W.Y., Reiser I.W., and Chou S.Y. Risk factors for acute renal insufficiency induced by diuretics in patients with congestive heart failure. Am J Kidney Dis 47 (2006) 798-808
11. Rejnmark L., Vestergaard P., and Mosekilde L. Fracture risk in patients treated with loop diuretics. J Intern Med 259 (2006) 117-124
12. Rejnmark L., Vestergaard P., and Mosekilde L. Reduced fracture risk in users of thiazide diuretics. Calcif Tissue Int 76 (2005) 167-175
13. Eshaghian S., Horwich T.B., and Fonarow G.C. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97 (2006) 1759-1764
14. Krum H., and Cameron P. Diuretics in the treatment of heart failure: mainstay of therapy or potential hazard?. J Card Fail 12 (2006) 333-335
15. Domanski M., Tian X., Haigney M., et al. Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail 12 (2006) 327-332
16. Galve E., Mallol A., Catalan R., et al. Clinical and neurohumoral consequences of diuretic withdrawal in patients with chronic, stabilized heart failure and systolic dysfunction. Eur J Heart Fail 7 (2005) 892-898
17. Brater D.C. Diuretic therapy. N Engl J Med 339 (1998) 387-395
18. Mazur J.E., Devlin J.W., Peters M.J., et al. Single versus multiple doses of acetazolamide for metabolic alkalosis in critically ill medical patients: a randomized, double-blind trial. Crit Care Med 27 (1999) 1257-1261
19. Shankar S.S., and Brater D.C. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 284 (2003) F11-F21
20. Andreasen F., Hansen U., Husted S.E., et al. The pharmacokinetics of frusemide are influenced by age. Br J Clin Pharmacol 16 (1983) 391-397
21. Sica D.A., and Gehr T.W.B. Diuretic combinations in refractory edema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 30 (1996) 229-249
22. Murray M.D., Haag K.M., Black P.K., et al. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy 17 (1997) 98-106
23. Vargo D.L., Kramer W.G., Black P.K., et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 57 (1995) 601-609
24. Cocco G., Iselin H.U., Strozzi C., et al. Magnesium depletion in patients on long-term chlorthalidone therapy for essential hypertension. Eur J Clin Pharmacol 32 (1987) 335-338
25. Sica D.A. Metolazone and its role in edema management. Cong Heart Fail 9 (2003) 100-105
26. Davis B.R., Piller L.B., Cutler J.A., et al. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 113 (2006) 2201-2210
27. Gardiner P., Schrode K., Quinlan D., et al. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol 29 (1989) 342-347
28. Sica D.A. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 10 (2005) 23-29
29. Ravis W.R., Reid S., Sica D.A., et al. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol 45 (2005) 810-821
30. van Vliet A.A., Donker A.J., Nauta J.J., et al. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 71 (1993) 21A-28A
31. Masoudi F.A., Gross C.P., Wang Y., et al. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation 112 (2005) 39-47
32. Dinsdale C., Wani M., Steward J., et al. Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age. Age Ageing 34 (2005) 395-398
33. Soberman J.E., and Weber K.T. Spironolactone in congestive heart failure. Curr Hypertens Rep 2 (2000) 451-456
34. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
35. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
36. Pitt B., White H., Nicolau J., et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46 (2005) 425-431
37. Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108 (2003) 1831-1838
38. Bianchi S., Bigazzi R., and Campese V.M. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 46 (2005) 45-51
39. Tang W.H., Parameswaran A.C., Maroo A.P., et al. Aldosterone receptor antagonists in the medical management of chronic heart failure. Mayo Clin Proc 80 (2005) 1623-1630
40. Neuberg G.W., Miller A.B., O'Connor C.M., et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 144 (2002) 31-38
41. Abildgaard U., Aldershvile J., Ring-Larsen H., et al. Bed rest and increased diuretic treatment in chronic congestive heart failure. Eur Heart J 6 (1985) 1040-1046
42. Tsuyuki R.T., McKelvie R.S., Arnold J.M., et al. Acute precipitants of congestive heart failure exacerbations. Arch Intern Med 161 (2001) 2337-2342
43. De Pasquale C.G., Dunne J.S., Minson R.B., et al. Hypotension is associated with diuretic resistance in severe chronic heart failure, independent of renal function. Eur J Heart Fail 7 (2005) 888-891
44. McLay J.S., McMurray J.J., Bridges A.B., et al. Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure. Am Heart J 126 (1993) 879-886
45. Sica D.A. Drug absorption in the management of congestive heart failure: loop diuretics. Congest Heart Fail 9 (2003) 287-292
46. Bleske B.E., Welage L.S., Kramer W.G., et al. Pharmacokinetics of torsemide in patients with decompensated and compensated congestive heart failure. J Clin Pharmacol 38 (1998) 708-714
47. Feenstra J., Heerdinck E.R., Grobbee D.E., et al. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure. Arch Intern Med 162 (2002) 262-270
48. Kelly R.A., Wilcox C.S., Mitch W.E., et al. Response of the kidney to furosemide. II. Effect of captopril on sodium balance. Kidney Int 24 (1983) 233-239
49. Ellison D.H., Velazquez H., and Wright F.S. Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion. J Clin Invest 83 (1989) 113-126
50. Loon N.R., Wilcox C.S., and Unwin R.J. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 36 (1989) 682-689
51. Sica D.A. Diuretic-related side effects: development and treatment. J Clin Hypertens (Greenwich) 6 (2004) 532-540
52. Gheorghiade M. The clinical effects of vasopressin receptor antagonists in heart failure. Cleve Clin J Med 73 Suppl 2 (2006) S24-S29
53. Loon N.R., and Wilcox C.S. Mild metabolic alkalosis impairs the natriuretic response to bumetanide in normal human subjects. Clin Sci (Lond) 94 (1998) 287-292
54. O'Connell J.E., and Colledge N.R. Type IV renal tubular acidosis and spironolactone therapy in the elderly. Postgrad Med J 69 (1993) 887-889
55. Cappola T.P., Kass D.A., Nelson G.S., et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104 (2001) 2407-2411
56. Niizeki T., Takeishi Y., Arimoto T., et al. Hyperuricemia associated with high cardiac event rates in the elderly with chronic heart failure. J Cardiol 47 (2006) 219-228
57. Gurwitz J.H., Kalish S.C., Bohn R.L., et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol 50 (1997) 953-959
58. Morgan D.B., and Davidson C. Hypokalemia and diuretics: an analysis of publications. BMJ 280 (1980) 905-908
59. Sica D.A., Struthers A.D., Cushman W.C., et al. Importance of potassium in cardiovascular disease. J Clin Hypertens 4 (2003) 198-206
60. Macdonald J.E., and Struthers A.D. What is the optimal serum potassium level in cardiovascular patients?. J Am Coll Cardiol 43 (2004) 155-161
61. Sica D.A., and Hess M. Aldosterone receptor antagonism: interface with hyperkalemia in heart failure. Congest Heart Fail 10 (2004) 259-264
62. Whang R., Oei T.O., Aikawa J.K., et al. Predictors of clinical hypomagnesemia. Hypokalemia, hypophosphatemia, hyponatremia, and hypocalcemia. Arch Intern Med 144 (1984) 1794-1796
63. Sica D.A., Frishman W.H., and Cavusoglu E. Magnesium, potassium, and calcium as potential cardiovascular disease therapies. In: Frishman W., Sonnenblick E., and Sica D.A. (Eds). Cardiovascular pharmacotherapeutics (2003), McGraw-Hill, New York 177-190